ADARx Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.90B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention wit...